Gain a deeper understanding of Cardio IQ® Ion Mobility—cutting-edge technology in lipid subclass characterization—by choosing a link below, or simply scroll through the entire section.

Advantages of Cardio IQ®
What Cardio IQ® provides
Clinical applications of Cardio IQ®
Consider Cardio IQ®

Cardio IQ® Ion Mobility is the latest technology evolution, with a pedigree reaching back to the first lipoprotein characterization work at University of California, Berkeley

Ion Mobility image 2


 

Cardio IQ® Ion Mobility: Advantages

Cardio IQ® Ion Mobility represents the future of advanced lipid analysis in clinical practice. By moving beyond the past compromises of other advanced lipid subclass measurements, this tool provides physicians with increased insights to better manage treatment decisions for their patients.

Cardio IQ® Ion Mobility is strongly supported by literature and experts in the field as the leading method for lipoprotein size assessment. It is being established as the new standard in the field. Dr Ron Krauss, developer of segmented gradient gel technology, developed Cardio IQ® Ion Mobility as the next generation in lipid subclass separation.

 

What the Cardio IQ® Ion Mobility Test provides

  • Direct, accurate, and reproducible measurement of lipoprotein particles
  • Insights that allow customization of therapy for potential improvement in patient outcomes

The 4 key subclasses from the Cardio IQ® Ion Mobility analysis that are most important for clinical management are displayed on the first summary page of the Cardio IQ® Report in the lipoprotein subfractionation section:

Ion Mobility good and bad chart

Clinical applications of the Cardio IQ® Ion Mobility Test

The presence of small LDL subclasses has long been associated with increased CVD risk and progression of vessel damage, inflammation, and eventually, atherosclerotic disease. Early observations from analytical ultracentrifugation and gradient gel electrophoresis regarding the association of lipoprotein subclasses with risk led to the definition of an “atherogenic lipoprotein phenotype” (ALP).

ALP is characterized by a predominance of small LDL particles and associated with elevations of triglycerides and reductions in HDL cholesterol and large HDL particles. Further, the particle diameter of the major LDL peak could be used in the majority of individuals to discriminate carriers of this higher-risk phenotype (referred to as small LDL diameter predominate, or pattern B) from noncarriers (larger LDL diameter, or pattern A).

The Malmö Diet and Cancer Study indicates that Ion Mobility-determined subclasses have been associated with increased CVD risk. An analysis of 4594 initially healthy men and women (mean follow-up 12.2 years, 377 incident cardiovascular events, with 206 being coronary events) showed an increase in the number of LDL particles, small and medium LDL subclasses from Cardio IQ® Ion Mobility, along with elevated triglycerides, to be positively associated with increased event risk. This same study revealed large HDL subclass levels to be inversely associated with event risk, thus supporting the cardioprotective aspect of high HDL-C. This finding is consistent with previous literature defining ALP.

Ion Mobility image 3

Treatment via pharmaceutical options such as statins, niacin or fibrates, as well as lifestyle change, has been impactful in correcting ALP, ie, reducing LDL particle numbers, changing the distribution of LDL particles from atherogenic small LDL to larger LDL particles, and shifting small HDL particles to large HDL particles associated with cardioprotective mechanisms.


Consider Cardio IQ® Ion Mobility: A more powerful approach to lipid subclass characterization

By taking into consideration a more powerful risk assessment based on total LDL particles and key lipid subclasses, healthcare practitioners may identify residual risk not revealed by the lipid panel or the Lipoprotein Phenotype Pattern B.

Ion Mobility image 4

Discover more tests that may help you deliver customized treatment to your patients at risk for cardiovascular disease.